tbuckley/cabot-search huggingface dataset:
Recurrent epistaxis in an adolescent
Authors: Oliver McLaren, Natalie Ronan
Journal: BMJ (2019)

A 16 year old boy presented to the ear, nose, and throat (ENT) outpatient clinic with recurrent non-traumatic nosebleeds, which had occurred daily over the preceding year. The bleeds were self limiting, lasting 5-10 minutes at a time. The patient had never presented to hospital with the nosebleeds, and noticed no benefit from a 10 day course of antiseptic cream prescribed by his general practitioner. He had no medical history and was unsure of any relevant family …
Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Authors: M. Sebastian, W.E.E. Eberhardt, C. Losem, C. Bernhardt, C. Maintz, N.W. Marschner, M. Jänicke, A. Fleitz, L. Spring, J. Sahlmann, A. Karatas, A. Hipper, W. Weichert, P. Hoffknecht, C. Grah, A. Rittmeyer, F. Griesinger, M. Thomas
Journal: Annals of Oncology (2019)
Abstract 16673: Exome Sequencing in a Pediatric Cardiomyopathy Cohort: Findings From the Pediatric Cardiomyopathy Registry
Authors: Stephanie M Ware, James D Wilkinson, Muhammad Tariq, Jeffrey A Schubert, Arthi Sridhar, Steven D Colan, Ling Shi, Charles E Canter, Daphne T Hsu, Steven A Webber, Debra A Dodd, Melanie D Everitt, Paul F Kantor, Linda J Addonizio, John L Jefferies, Joseph W Rossano, Elfriede Pahl, Paolo Rusconi, Wendy K Chung, Teresa M Lee, Jeffrey A Towbin, Ashwin K Lal, Surbhi Bhatnagar, Bruce J Aronow, Phillip Dexheimer, Lisa J Martin, Erin M Miller, Hiedy Razoky, Jason D Czachor, Steven E Lipshultz
Journal: Circulation (2017)

Introduction: Pediatric cardiomyopathy (CM) is a genetically heterogeneous high-risk condition, with a large proportion of cases labeled as idiopathic. Hypothesis: A comprehensive sequencing approa...
Interferon ɣ (IFN-ɣ) gene signature and tryptophan 2,3-dioxygenase 2 (TDO2) gene expression: a potential predictive composite biomarker for linrodostat mesylate (BMS-986205; indoleamine 2,3-dioxygenase 1 inhibitor [IDO1i]) + nivolumab (NIVO)
Authors: J. Luke, L.L. Siu, J. Santucci-Pereira, D. Nelson, E.H. Kandoussi, B. Fischer, M. Wind-Rotolo, D. Greenawalt, Y. Ishii
Journal: Annals of Oncology (2019)
Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers
Authors: P.R. Clingan, A.M. Mant, G.E. Richardson, D.M. Kowalski, P. Koralewski, I. Lugowska, A. Dechaphunkul, C. Charoentum, A. Sookprasert, V. Sriuranpong, A. Akopov, V. Kozlov, N. Fadeeva, B. Kasparov, N.V. Kovalenko, V. Oschepkov, L. Gorelik, Y. Kunes, J. Oliviero, D.L. Harris
Journal: Annals of Oncology (2019)
Associations Between Social Risk Factors and Surgical Site Infections After Colectomy and Abdominal Hysterectomy
Authors: Andrew C. Qi, Kate Peacock, Alina A. Luke, Abigail Barker, Margaret A. Olsen, Karen E. Joynt Maddox
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Surgical site infection (SSI) is an important patient safety outcome. Although social risk factors have been linked to many adverse health outcomes, it is unknown whether such factors are associated with higher rates of SSI. <h3>Objectives</h3> To determine whether social risk factors, including race/ethnicity, insurance status, and neighborhood income, are associated with higher rates of SSI after colectomy or abdominal hysterectomy, 2 surgical procedures for which SSI rates are publicly reported and included in pay-for-performance programs by Medicare and other groups. <h3>Design, Setting, and Participants</h3> This cross-sectional study analyzed adults undergoing colectomy or abdominal hysterectomy, as captured in State Inpatient Databases for Arizona, Florida, Iowa, Massachusetts, Maryland, New York, and Vermont. Operations were performed in 2013 through 2014 at general acute care hospitals in the United States. Data analysis was conducted from October 2018 through June 2019. <h3>Exposures</h3> Colectomy or hysterectomy. <h3>Main Outcomes and Measures</h3> Postoperative complex SSI rates. <h3>Results</h3> A total of 149 741 patients met the inclusion criteria, including 90 210 patients undergoing colectomies (mean [SD] age, 63.4 [15.6] years; 49 029 [54%] female; 74% white, 11% black, 9% Hispanic, and 5% other or unknown race/ethnicity) and 59 531 patients undergoing abdominal hysterectomies (mean [SD] age, 49.8 [11.8] years; 100% female; 52% white, 26% black, 14% Hispanic, and 8% other or unknown race/ethnicity). In the colectomy cohort, 34% had private insurance, 52% had Medicare, 9% had Medicaid, and 5% had other or unknown insurance or were uninsured; 24% were from the lowest quartile of median zip code income. In the hysterectomy cohort, 57% had private insurance, 16% had Medicare, 19% had Medicaid, and 3% had other or unknown insurance or were uninsured; 27% were from the lowest-income zip codes. Within 30 days of surgery, SSI rates were 2.55% for the colectomy cohort and 0.61% for the hysterectomy cohort. For colectomy, black race (adjusted odds ratio [AOR], 0.71; 95% CI, 0.61-0.82) was associated with lower odds of SSI, whereas Medicare (AOR, 1.25; 95% CI, 1.10-1.41), Medicaid (AOR, 1.23; 95% CI, 1.06-1.44), and low neighborhood income (AOR, 1.14; 95% CI, 1.01-1.29) were associated with higher odds of SSI. For hysterectomy, no social risk factors that were examined in this study had statistically significant associations with SSI after adjustment for clinical risk. <h3>Conclusions and Relevance</h3> Inconsistent associations between social risk factors and SSIs were found. For colectomy, infection prevention programs targeting low-income groups may be important for reducing disparities in this postoperative outcome, and policy makers could consider taking social risk factors into account when evaluating hospital performance.
Impact of Antithymocyte Globulin-Containing Conditioning Regimens on Patients Undergoing Allogeneic Stem Cell Transplantation for Progressive Myelodysplastic Syndrome: A Report From the SFGM-TC Group
Authors: Ibrahim Yakoub-Agha, Gandhi Damaj, Marie Robin, Stephane Vigouroux, Alice Garnier, Mauricette Michallet, Jean El-Cheikh, Bruno Lioure, Audrey Simon, Jacques-Olivier Bay, Pierre Bordigoni, Nathalie Contentin, Natacha Maillard, Eric Deconinck, Simona Lapusan, Gaelle Guillerm, Faezeh Legrand, Evelyne Marry, Mohamad Mohty, Alain Duhamel
Journal: Blood (2011)
Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): Results from the randomized phase III study (SANET-ep)
Authors: J. Xu, L. Shen, Z. Zhou, J. Li, C. Bai, Y. Chi, Z. Li, N. Xu, R. Jia, E. Li, T. Liu, Y. Bai, Y. Yuan, X. Li, X. Wang, J. Chen, J. Ying, J. Li, S. Fan, W. Su
Journal: Annals of Oncology (2019)
Does Hemoglobin S in Sickle Cell Trait and Sickle Cell Anemia Induce Higher Hemostatic Potential?
Authors: Bhavna Ansuya Mahadeb, Laurence Rozen, Denis Fondjie Noubouossie, Tatiana Besse-Hammer, Andre Efira, Philippe Hermans, Beatrice Gulbis, Marie-Agnes Azerad, Anne C Demulder
Journal: Blood (2014)
Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the phase III SPARTAN study
Authors: M.R. Smith, F. Saad, S. Chowdhury, S. Oudard, B.A. Hadaschik, J.N. Graff, D. Olmos, P.N. Mainwaring, J.Y. Lee, H. Uemura, P. De Porre, A. Smith, K. Zhang, A. Lopez-Gitlitz, E.J. Small
Journal: Annals of Oncology (2019)
Non-Hematopoietic Bone Marrow Cells Can Be Mobilized and Differentiate into Cardiomyocytes after Myocardial Infarction: Possible Contribution of Mesenchymal Stem Cells.
Authors: Hiroshi Kawada, Jun Fujita, Kentaro Kinjo, Yumi Matsuzaki, Mitsuyo Tsuma, Hiroko Miyatake, Yukari Muguruma, Hideyuki Okano, Tomomitsu Hotta, Keiichi Fukuda, Kiyoshi Ando
Journal: Blood (2004)
ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Authors: M.O. Butler, C. Robert, S. Negrier, G.K. In, J. Walker, I. Krajsova, V.G. Atkinson, J. Hansson, E. Kapiteijn, C. Loquai, H.M. Shaw, T. Cheng, S. Mansard, J.J. Grob, M. Guidoboni, M. Mehta, P.A. Ascierto, A. Diab
Journal: Annals of Oncology (2019)
Affordability Boards — The States’ New Fix for Drug Pricing
Authors: Tara Sklar, Christopher Robertson
Journal: New England Journal of Medicine (2019)

Interview with Prof. Tara Sklar on recent state laws creating prescription-drug affordability boards. (10:03)Download A new Maryland law that creates a prescription-drug affordability board to help the state regulate drug prices may be a harbinger of what’s to come in drug-pricing legislation. The law permits cost reviews when drug prices or price increases exceed specified thresholds.
Abstract P333: Post-Stroke Outcomes Vary by Etiologic Stroke Subtype in the Atherosclerosis Risk in Communities Study
Authors: Sara B Jones, Souvik Sen, Steven Offenbacher, Kamakshi Lakshminarayan, Wayne D Rosamond
Journal: Circulation (2012)

Background: Early risk of recurrent stroke and mortality after stroke differ by subtype, but less is known about long-term outcomes and all-cause hospital readmission. Understanding these differences may have implications for secondary prevention and treatment of stroke. We examined rates of recurrent stroke, all-cause hospital readmission, and mortality by index stroke etiologic subtype. Methods: Atherosclerosis Risk in Communities Study cohort participants with a definite/probable first-ever stroke were identified and followed until death or 12/31/2008. The association between index and recurrent stroke subtype and median times to first recurrent stroke and first hospital admission were assessed according to index stroke subtype (infarction: thrombotic, cardioembolic [CE], and lacunar; hemorrhagic: subarachnoid [SAH] and intraparenchymal [IPH]). Incidence rates of recurrent stroke, all-cause hospitalization, and death were calculated by index subtype. Reasons for hospitalization were identified using primary ICD-9 codes. Recurrent stroke outcomes for hemorrhagic subtypes are not reported here due to small numbers of events. Results: A total of 987 persons with first-ever stroke were identified and followed for an average 5.3±5.0 years post-stroke (48.7% thrombotic, 20.0% CE, 18.5% lacunar, 8.6% IPH, and 4.2% SAH). During follow-up, there were 183 recurrent strokes among 147 participants, 3234 hospitalizations among 746 participants, and 529 deaths. Only 139 (14.1%) participants had none of these events during follow up. Roughly 70% of recurrent strokes were of the same subtype as the index stroke; however, only a third were the same when the index stroke was lacunar. Time to first recurrent stroke varied by subtype (median days [range]; thrombotic, 930.5[2-4692]; CE, 271[2-5566]; lacunar, 789[5-4361]) while time to first hospitalization was more similar, ranging from 102.5[4-3634] among CE to 370[6-6506] among IPH. Incidence rates of recurrent stroke (per 100 person-years) were highest after lacunar stroke (4.4) followed by thrombotic (3.7), and CE (2.7). All-cause hospital readmission rates were: thrombotic (58.8), CE (88.9), lacunar (60.1), IPH (59.4), and SAH (35.3); and mortality rates were: thrombotic (9.0), CE (15.1), lacunar (7.4), IPH (22.3), and SAH (7.3). Non-stroke related hospitalizations, including heart failure, ischemic heart disease, and diabetes were not uncommon after stroke, particularly after thrombotic and CE strokes. Conclusion: While the highest mortality was observed for IPH, there was significant burden of recurrent stroke and all-cause hospitalization for other stroke subtypes, especially lacunar and CE. Hospital readmission rates were high for all subtypes, suggesting there may be opportunities to reduce post-stroke readmissions. Prevention efforts tailored according to etiologic stroke subtype may be warranted.
The effect of treatment line on the efficacy of anlotinib hydrochloride in advanced alveolar soft part sarcoma patients
Authors: Z. Fang, Y. Yao, J. Cai, Y. Chi, S. Wang, G. Huang, Q. Cai, G. Shang, G. Wang, G. Qu, Q. Wu, Y. Jiang, J. Song, J. Chen, Z. Cai, X. Zhu, C. Bai, Y. Lu, Z. Yu, J. Shen
Journal: Annals of Oncology (2019)
A novel machine-learning-derived genetic score correlates with measurable residual disease and is highly predictive of outcome in acute myeloid leukemia with mutated NPM1
Authors: Nikhil Patkar, Anam Fatima Shaikh, Chinmayee Kakirde, Shrinidhi Nathany, Hridya Ramesh, Prasanna Bhanshe, Swapnali Joshi, Shruti Chaudhary, Sadhana Kannan, Syed Hasan Khizer, Gaurav Chatterjee, Prashant Tembhare, Dhanalaxmi Shetty, Anant Gokarn, Sachin Punatkar, Avinash Bonda, Lingaraj Nayak, Hasmukh Jain, Navin Khattry, Bhausaheb Bagal, Manju Sengar, Sumeet Gujral, Papagudi Subramanian
Journal: Blood Cancer Journal (2019)
The role of vitamin E in the prevention of cancer: Meta-analysis of randomized controlled trials
Authors: A. Alkhenizan, K. Hafez
Journal: Journal of Clinical Oncology (2006)

1017 Background: Several in vitro studies showed antioxidant vitamins to have a significant protective effect against cancer. We did a meta-analysis of Randomized Controlled Trials (RCTs) to evaluate the role of vitamin E supplements in the prevention of Cancer in adults Methods: We included RCTs, in which outcomes of the intake of vitamin E supplement alone or with other supplements, were compared to a control group.The primary outcomes were total mortality, cancer mortality, total incidence of Cancer, incidence of Lung, stomach, esophageal, pancreatic, prostate, breast and thyroid cancers. All identified trials were reviewed independently by the two reviewers to determine whether trials should be included or excluded. The quality of all included studies was scored independently by the two reviewers. RevMan, version 4.2 was used for the data analysis. Results: Twelve studies met inclusion criteria, including 167025 participants. There were no statistically significant differences in total mortality (RR 0.99; 95%CI 0.96–1.03), cancer incidence (OR 0.96; 95%CI 0.92, 1.01), and cancer mortality (OR 1.00; 95%CI 0.96–1.03) among the different groups of patients included in this meta-analysis. Vitamin E did not reduce the incidence of any type of cancer that was available for analysis; However there was a statistically significant reduction in the incidence of prostate cancer in patients receiving vitamin E, RR 0.85 [0.73–0.96, NNT=500]. Conclusions: Vitamin E supplementation was not associated with a reduction in total mortality or cancer incidence, and cancer mortality, but it was associated with a statistically significant reduction in the incidence of prostate cancer. Vitamin E can be used in the prevention of Prostate cancer in men who are at high risk of prostate cancer. No significant financial relationships to disclose.
TP53 and ATM co-mutation predicts response to immune checkpoint inhibitors in non-small cell lung cancer
Authors: Y. Chen, G. Chen, J. Li, C. Huang, Y. Li, J. Lin, L.Z. Chen, J.P. Lu, Y.Q. Wang, C.X. Wang, L.K. Pan, X.F. Xia, X. Yi, C.B. Chen, X.W. Zheng, Z.Q. Guo, J.J. Pan
Journal: Annals of Oncology (2019)
IFN-γ/IL-10 ratio as predictive biomarker for response to anti-PD-1 therapy in metastatic melanoma patients
Authors: E.F. Giunta, G. Barra, V. De Falco, P. Vitale, N. Zanaletti, M. Terminiello, V. Caputo, S. Napolitano, P.P. Vitiello, D. Ciardiello, V. Belli, G. Brancaccio, G. Argenziano, R. De Palma, F. Ciardiello, T. Troiani
Journal: Annals of Oncology (2019)
Toward Evidence-Based Policy Making to Reduce Wasteful Health Care Spending
Authors: Karen E. Joynt Maddox, Mark B. McClellan
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Analysis of tumour hyperprogression (HP) with nivolumab (Nivo) in randomized, placebo (Pbo)-controlled trials
Authors: M. Reck, Y. Feng, H.R. Kim, G. Plautz, Y.-K. Kang, T.K. Owonikoko, P. Nghiem, J. Sheng
Journal: Annals of Oncology (2019)
Obese and overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab
Authors: B. Cybulska-Stopa, K. Regulski, R. Wiśniowski, M. Rajczykowski, R. Suwinski, M. Domagała-Haduch, K. Piejko, A.P. Drosik, I. Bar-Letkiewicz, L. Rauch, T. Szczęsny, M. Ziobro, J. Mackiewicz
Journal: Annals of Oncology (2019)
Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: An exploratory analysis of the GIM2 trial
Authors: B. Conte, M. Bruzzone, M. Lambertini, F. Poggio, E. Blondeaux, M. De Laurentiis, E. Valle, F. Cognetti, C. Nisticò, S. De Placido, M.C. Merlano, T. Gamucci, F. Montemurro, M. Ceppi, L. Del Mastro
Journal: Annals of Oncology (2019)
TCTAP A-098 Differential Clinical Outcomes Between Angiographic Complete Versus Incomplete Coronary Revascularization, According to the Presence of Chronic Kidney Disease in the Drug-eluting Stent Era
Authors: Jihoon Kim, Joo Myung Lee, Ki Hong Choi, Tae-Min Rhee, Doyeon Hwang, Jonghanne Park, Taek Kyu Park, Jeong Hoon Yang, Young Bin Song, Jin Ho Choi, Joo-Yong Hahn, Seung Hyuk Choi, Hyeon-Cheol Gwon
Journal: Journal of the American College of Cardiology (2018)
Sequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany
Authors: W. Brückl, M. Reck, E. Laack, B. Hermes, J. Rawluk, R.M. Huber, C. Hoffmann, A. Schueler
Journal: Annals of Oncology (2019)
Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061)
Authors: E. Van Cutsem, M. Amonkar, C.S. Fuchs, M. Alsina, M. Özgüroğlu, Y.-J. Bang, H.C. Chung, K. Muro, E. Goekkurt, A. Benson, W. Sun, Z.A. Wainberg, J. Norquist, X. Chen, C.-S. Shih, K. Shitara
Journal: Annals of Oncology (2019)
Heterogeneity of circulating tumor cells in primary breast cancer patients.
Authors: Branislav Bystricky, Marian Karaba, Juraj Benca, Ludmila Vavrova, Jan Markus, Michal Konecny, Daniel Pindak, Jozef Sufliarsky, Jozef Mardiak, Michal Mego
Journal: Journal of Clinical Oncology (2015)

e22037 Background: Circulating tumor cells (CTCs) are tumor cells in peripheral blood and represent a heterogeneous population of cells with different phenotypes and biological value. The aim of this study was to characterize CTCs based on the expression of epithelial and mesenchymal markers in primary breast cancer patients before surgery. Methods: This prospective translational study consists of 133 treatment naïve primary breast cancer patients that underwent surgery at National Cancer Institute in Slovakia from January to December 2013. Peripheral blood for CTCs detection was drawn prior to surgery and CTCs were detected using AdnaTest Breast Cancer Select/Detect for epithelial markers (EpCAM, MUC-1, HER2) and AdnaTest Breast Cancer EMT/Stem Cell kit for epithelial to mesenchymal transition (EMT) and stem cell markers (Twist, PI3Ka, Akt2, ALDH1). Presence of CTCs was correlated with clinical and pathological variables. Results: Median age was 59 year (range: 25-82 years). Majority of patients had tumors < 2 cm (67%), had uninvolved axillary lymph nodes (63%), 84% were hormone receptor positive and 82.7% HER-2 negative. Triple-negative were only 10.5% of patients, while HER2 was amplified in 17% of patients and 38% had grade 2 disease. Totally, CTCs were detected in 20.3% of patients. CTCs with only epithelial markers were present in peripheral blood of 9% patients; CTCs with EMT/stem cell phenotype were present in 15% of patients, while CTCs in 4.5% of patients exhibited both epithelial and EMT/stem cell markers. There was no association between the presence of CTCs and analysed patients/tumor characteristics. Conclusions: Our data support the concept of heterogeneity of microscopic disease in primary breast cancer. Longer follow-up is needed to establish prognostic value of CTCs with EMT/stem cell phenotype in primary breast cancer.
Adaption of pancreatic cancer cells to AKT1 inhibition induces the acquisition of cancer stem-cell like phenotype through upregulation of mitochondrial functions
Authors: H. Arasanz, M. Zuazo, E. Santamaría, A.I. Bocanegra, M. Gato-Cañas, G. Fernández-Hinojal, C. Hernández-Saez, J. Fernández-Irigoyen, E. Santamaria, C. Rodríguez-Ortigosa, G. Kochan, R. Vera, D. Escors
Journal: Annals of Oncology (2019)
Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
Authors: S.S. Ramalingam, J.E. Gray, Y. Ohe, B.C. Cho, J. Vansteenkiste, C. Zhou, T. Reungwetwattana, Y. Cheng, B. Chewaskulyong, R. Shah, K.H. Lee, P. Cheema, M. Tiseo, T. John, M.C. Lin, F. Imamura, R. Hodge, Y. Rukazenkov, J.-C. Soria, D. Planchard
Journal: Annals of Oncology (2019)
Comprehensive genomic profiling (CGP) of mixed hepatocellular cholangiocarcinomas (cHCC-CCA)
Authors: K. Murugesan, M. Javle, A.B. Schrock, N. Ngo, G.M. Frampton, B.M. Alexander, V.A. Miller, T. Bekaii-Saab, L.A. Albacker, J.S. Ross, S.M. Ali
Journal: Annals of Oncology (2019)